dna-strand.jpgSan Diego – Human Genome Sciences recently received a favorable ruling in a patent dispute with Eli Lilly concerning the validity of a patent for a gene sequence for use in developing treatments for people with immune diseases.

Eli Lilly originally contested the European patent owned by Human Genome on the grounds that the patent was too vague